Schlagwort: Value creation
Part II: The Best Asset Doesn’t Have a Passport
For many years, Western biotech companies viewed China primarily as a manufacturing base and, increasingly, as an attractive commercial market. Today, that perspective is...
Mutares baut Chemiegeschäft aus
Die Beteiligungsgesellschaft Mutares (ISIN: DE000A2NB650, MarketCap: 726 Mio. EUR) stärkt ihr Segment Chemicals & Materials mit einer weiteren Akquisition. Das Unternehmen hat den Erwerb...
Mutares: Exit-Dynamik sorgt für guten Jahresauftakt
Die Münchener Beteiligungsgesellschaft Mutares (ISIN: DE000A2NB650) hat heute (12.05.2026) ihre neuen Geschäftszahlen vorgelegt. Der Konzern steigerte im ersten Quartal 2026 seinen Umsatz um 10...
‘‘We build a leading global platform for precision healthcare‘‘
Leo International Precision Health AG (LIPH) is an investment holding company (WKN: 549060; ticker: LEOW) that has been listed on the stock exchange since...
Comparing late-stage vs. early-stage investment strategies
It is generally believed that, as projects advance in discovery research, little value is created because the products are still years away from the...